NanoString GeoMx™ Digital Spatial Profiler

Clinical trials are underway to examine the efficacy of various immune checkpoint inhibitor molecules, for the treatment of cancer. Watch this video to learn about the companion diagnostics that are enabling the identification of patients who could benefit from these treatments.

The genetic code of all 500,000 UK Biobank volunteer participants will be sequenced by researchers at the Wellcome Sanger Institute in the UK and deCODE genetics in Iceland. This project is the single most ambitious sequencing programme in the world undertaken by a public-private partnership, and will power the next wave of genetic and health research

A healthy microbiome increases the efficacy of drugs such as checkpoint inhibitors which take the blindfold off of the immune system, allowing it to recognize, attack, and kill cancer cells. Unfortunately, 70% of cancer patients don’t respond to this drug treatment due to severely damaged microbiomes which have limited kinds of bacteria.